Access to new technologies in multipatented vaccines: challenges for Brazil

Possas, Cristina; Antunes, Adelaide Maria de Souza; Mendes, Fernanda de Souza Nogueira Sardinha; Schumacher, Suzanne de Oliveira Rodrigues; Felzemburgh, Ridalva Dias Martins; Homma, Akira

doi:10.1038/nbt.3244

Cited by 16 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a major challenge are the concerning recent SARS-CoV-2 variants (UK, B.1.1.7; South Africa, B.1.351; and Brazil P1), requiring from scientists a redesign of approved vaccines. Finally, other issues such as limited global access to multipatented vaccines [ 22 ], sharp decline in global vaccine coverage, related to “vaccine hesitancy,” and vaccine refusal [ 23 ] will probably contribute as well to reduce the impact of the new SARS-CoV-2 vaccines. In order to meet global challenges in vaccine development for emerging diseases, a new vaccine preparedness initiative has been created in 2017 by governments and international organizations.…”

Section: Covid-19 Vaccines: Breakthroughs and Constraintsmentioning

confidence: 99%

COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster

et al. 2021

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic exposed a world surprisingly unprepared to respond to the new epidemiological scenario, even the developed countries, in spite of warnings from scientists since the 1990s. These alerts warned on the risks of an exponential increase in emergence of potentially pandemic zoonotic infectious diseases related to disruptive ecological niches in different regions of the globe, such as H1N1 Influenza, SARS, MERS, Zika, avian flu, swine flu, and Ebola, and also on the risks of a future and more lethal Disease X. We examine this global public health failure in anticipating and responding to the pandemic, stressing the urgent need for an innovative global pandemic preparedness system in the current transition from linear economy to a circular economy. Evidence provided here indicates that this novel preventive-based and resource-saving preparedness system could contribute to reverse the detrimental impacts of the pandemic on global economy and increase its resilience. Individual protection, contact tracing, and lockdown have proved to be just partially effective to respond to the spillover of viral zoonosis into the human population, and for most of these pathogens, vaccines are not yet available. As for COVID-19 vaccines, in spite of the extraordinary investments and unprecedented advances in innovative vaccines in few months, most of these products are expected to be available to more vulnerable developing countries’ populations only by mid-2022. Furthermore, even when these vaccines are available, constraints such as low efficacy, waning immunity, new concerning COVID-19 variants, adverse events, and vaccine hesitancy might possibly restrict their public health impact and could contribute to aggravate the pandemic scenario. Considering these constraints and the severe global economic and social crises resulting from the lack of adequate preparedness and delayed effective response to COVID-19 and possibly to a future Disease X, we propose a pro-active global eco-social pandemic preparedness system. This novel system, based on One Health paradigm and on artificial intelligence and machine learning, is expected to incorporate “spillover” foresight and management into global preparedness and timely response. Designed to mitigate damage from outbreaks and minimize human morbidity and mortality, this approach to pandemic foresight and preparedness will be key to prevent a global disaster.

show abstract

Section: Covid-19 Vaccines: Breakthroughs and Constraintsmentioning

confidence: 99%

COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there are some constraints, particularly in developing countries, for their immediate incorporation into National Immunizations Programs-NIPs. Besides the very high prices of these multipatented vaccines [55] there are other infrastructure and logistic constraints, particularly with the Pfizer/BioNTech vaccine, such as the requirement of refrigeration under minus 75 C and once taken out kept refrigerated and used within five days. These constraints are particularly severe in countries of continental dimensions such as Brazil and India, with limited vaccine purchasing capacity and the need to transport these vaccines by road or by river to indigenous and rural communities in distant locations.…”

Section: Future Scenariosmentioning

confidence: 99%

Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era

et al. 2021

Self Cite

View full text Add to dashboard Cite

In this article, we present breakthroughs and challenges in vaccine development for COVID-19 pandemic, discussing issues related to pandemic preparedness and their implications for circular bioeconomy and sustainability. Notwithstanding the unprecedented accelerated speed of COVID-19 vaccine development, just 9 months after the emergence of the pandemic in Wuhan, China, benefiting from previous developments in SARS and MERS vaccines, significant gaps persist in global vaccine preparedness. These gaps include issues related to immunity and protection, particularly to the limited vaccine protection against recent emergence of concerning new viral variants in the UK, South Africa, and Brazil and the consequent need for vaccine redesign. We examine these gaps and discuss the main issues that could impact on global vaccine availability in the current pandemic scenario: (1) breakthroughs and constraints in development and production of leading global COVID-19 vaccines; (2) innovation and technological development advances and gaps, providing information on global patent assignees for COVID-19, SARS, and MERS vaccine patents; (3) local capacity for development and production of COVID-19, SARS, and MERS vaccines in three emerging agro-based countries (India, Brazil, and South Africa); and (4) future scenarios, examining how these issues and vaccines redesign for new SARS-CoV-2 variants could impact on global access to vaccines and implications for circular bioeconomy and sustainability in the post-COVID era.

show abstract

“…Patents are, from this perspective, a valuable tool for technological scanning and foresight of future trends in genomic vaccines. We analyze the global patent landscape for these multipatented vaccine processes and products (Possas et al 2015), trying to identify future scenarios up to 2030 for innovative breakthroughs in vaccines and immunotherapies for pandemic or potentially pandemic diseases, as indicated in Fig. 12.1.…”

Section: Conceptual Frameworkmentioning

confidence: 99%

Responsible Innovation in Industry: The Role of Firm’s Multi-Stakeholder Network

et al. 2021

View full text Add to dashboard Cite

the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Access to new technologies in multipatented vaccines: challenges for Brazil

Cited by 16 publications

References 10 publications

COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster

COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster

Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era

Responsible Innovation in Industry: The Role of Firm’s Multi-Stakeholder Network

Contact Info

Product

Resources

About